Thus, the recent Kidney Disease: Improving Global Outcomes (KDIGO) guideline for managing CKD considers it safe to continue or even initiate an SGLT-2 inhibitor when eGFR is below 20 mL/min/1.73 m2 and continue its use until the initiation of RRT [11]. This evidence concerns the gene SLC5A2 and chronic kidney disease.